A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

NCT06838273 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: BL-B01D1
DRUG: Osimertinib
DRUG: Osimertinib

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]